Investment Analysts’ Weekly Ratings Updates for Editas Medicine (EDIT)
A number of firms have modified their ratings and price targets on shares of Editas Medicine (NASDAQ: EDIT) recently: 3/1/2024 – Editas Medicine was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating. 2/29/2024 – Editas Medicine had its price target raised by analysts at Barclays PLC from $10.00 to $11.00. […]
More Stories
Bath Savings Trust Co Lowers Stock Position in Pool Co. (NASDAQ:POOL)
Bath Savings Trust Co decreased its position in Pool Co. (NASDAQ:POOL – Free Report) by 23.8% in the fourth quarter,...
Bath Savings Trust Co Lowers Holdings in Adobe Inc. (NASDAQ:ADBE)
Bath Savings Trust Co decreased its stake in Adobe Inc. (NASDAQ:ADBE – Free Report) by 9.0% during the fourth quarter,...
Janus Henderson Short Duration Income ETF (NYSEARCA:VNLA) is Rise Advisors LLC’s 5th Largest Position
Rise Advisors LLC lessened its holdings in Janus Henderson Short Duration Income ETF (NYSEARCA:VNLA – Free Report) by 13.5% during...
Rise Advisors LLC Trims Stake in Alliant Energy Co. (NASDAQ:LNT)
Rise Advisors LLC cut its stake in Alliant Energy Co. (NASDAQ:LNT – Free Report) by 4.6% in the fourth quarter,...
Rise Advisors LLC Has $150,000 Holdings in Target Co. (NYSE:TGT)
Rise Advisors LLC decreased its holdings in Target Co. (NYSE:TGT – Free Report) by 9.7% during the fourth quarter, according...
Rise Advisors LLC Sells 109 Shares of Prologis, Inc. (NYSE:PLD)
Rise Advisors LLC decreased its position in shares of Prologis, Inc. (NYSE:PLD – Free Report) by 18.0% during the fourth...